Li Yunyun, Gan Xiaoling, Li Fei, Hu Lina
Department of Gynecology and Obstetrics, The Yongchuan Hospital of Chongqing Medical University, Yongchuan District, Chongqing, PR China.
Department of Gynecology, Second Affiliated Hospital of Chongqing Medical University, Nanan District, Chongqing, PR China.
Immunol Invest. 2024 Feb;53(2):91-114. doi: 10.1080/08820139.2023.2284885. Epub 2023 Nov 21.
The epithelial ovarian carcinoma (EOC) is one of leading causes of cancer-related mortality in females. For some patients, complete resection cannot be achieved, thus neoadjuvant chemotherapy (NACT) following interval debulking surgery (IDS) could be an alternative choice. In general-held belief, cytotoxic chemotherapy is assumed to be immunosuppressive, because of its toxicity to dividing cells in the bone marrow and peripheral lymphoid tissues. However, increasing evidence highlighted that the anticancer activity of chemotherapy may also be related to its ability to act as an immune modulator. NACT not only changed the morphology of cancer cells, but also changed the transcriptomic and genomic profile of EOC, induced proliferation of cancer stem-like cells, gene mutation, and tumor-related adaptive immune response. This review will provide a comprehensive overview of recent studies evaluating the impact of NACT on cancer cells and immune system of advanced EOC and their relationship to clinical outcome. This information could help us understand the change of immune system during NACT, which might provide new strategies in future investigation of immuno-therapy for maintenance treatment of EOC.
上皮性卵巢癌（EOC）是女性癌症相关死亡的主要原因之一。对于一些患者来说，无法实现完全切除，因此间隔减瘤手术（IDS）后进行新辅助化疗（NACT）可能是一种替代选择。一般认为，细胞毒性化疗被认为具有免疫抑制作用，因为它对骨髓和外周淋巴组织中正在分裂的细胞有毒性。然而，越来越多的证据表明，化疗的抗癌活性也可能与其作为免疫调节剂的能力有关。NACT不仅改变了癌细胞的形态，还改变了EOC的转录组和基因组图谱，诱导了癌症干细胞样细胞的增殖、基因突变以及肿瘤相关的适应性免疫反应。本综述将全面概述近期评估NACT对晚期EOC癌细胞和免疫系统的影响及其与临床结局关系的研究。这些信息有助于我们了解NACT期间免疫系统的变化，这可能为未来EOC维持治疗的免疫治疗研究提供新策略。
